tailieunhanh - Báo cáo y học: " Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học quốc tế cung cấp cho các bạn kiến thức về ngành y đề tài: Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens | AIDS Research and Therapy BioMed Central Open Access Short report Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens Anuradha Ganesan 1 Lorie Benning2 Elizabeth T Golub2 Mark Riddle3 Nancy Crum-Cianflone4 Sybil Tasker1 Lisa Jacobson2 and Stephen J Gange2 Address infectious Disease Clinical Research Program Uniformed Services University of the Health Sciences National Naval Medical Center Bethesda Maryland USA 2Department of Epidemiology Johns Hopkins Bloomberg School of Public Health Baltimore Maryland USA 3Naval Medical Research Center Silver Spring Maryland USA and 4Infectious Disease Clinical Research Program Uniformed Services University of the Health Sciences Naval Medical Center San-Diego Calfornia USA Email Anuradha Ganesan - aug151947@ Lorie Benning-lbenning@ Elizabeth T Golub - egolub@ Mark Riddle - Nancy Crum-Cianflone - Sybil Tasker - Lisa Jacobson - ljacobson@ Stephen J Gange - sgange@ Corresponding author Published 22 June 2009 Received 12 March 2009 AIDS Research and Therapy 2009 6 13 doi l742-6405-6-l3 Accepted 22 June 2009 This article is available from http content 6 l l3 2009 Ganesan et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Antiretrovirals used to treat HIV-infected patients have the potential to adversely affect serum lipid profiles and increase the risk of cardiovascular disease which is an emerging concern among HIV-infected patients. Since boosted atazanavir and efavirenz are both considered preferred antiretrovirals a head to head comparison of their effects on .